Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Podcasts|September 26, 2022
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
CAR T therapies are potentially revolutionizing the treatment of acute lymphoblastic leukemia (ALL).
Advertisement
This month, we spoke with Craig Freyer, PharmD, BCOP, clinical pharmacy specialist at Penn Medicine, to learn about how CAR T therapies are potentially revolutionizing the treatment of acute lymphoblastic leukemia (ALL). In addition to discussing what makes ALL treatment unique from other cancer treatments, Freyer said pharmacists have important roles to play in managing cytokine release syndrome and potential neuro-toxicities.
Advertisement
Related to this article
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5